Our Publications

Lachaine J, Beauchemin C, Dodat F, Au Y, Evans WK, Leber B, Paulson K, Schuh A, Storring J. Evaluating the economic burden of acute myeloid leukemia in Canada. Acta Haematol. 2024 Feb 21. doi: 10.1159/000537725. Epub ahead of print. PMID: 38382483.

Jenny J. Ko, Lawrence Mbuagbaw, Scott Tyldesley, Jennifer Lowther, Katherine Sunderland, Catherine Royer, Mareva Faure, Corin MacPhail, Shoaib Faizi, Winson Y. Cheung, Richard Lee-Ying. Real-world evaluation of access-driven Canadian treatment sequences in progressive prostate cancer (REACTIVATE). Canadian Urological Association Journal. 2024 March 01. doi: https://doi.org/10.5489/cuaj.8620. 

Sandeep Sehdev, Joanna Gotfrit, Martine Elias, Barry D. Stein. Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action. Current Oncology. 2024 March 11. doi: https://doi.org/10.3390/curroncol31030110. (collaborators)

Lachaine J, Guinan K, Aw A, Banerji V, Fleury I, Owen C. Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada. Current Oncology. 2023; 30(5):4483-4498. https://doi.org/10.3390/curroncol30050339

Lachaine J, Charron JN, Gregoire JC, Hegele RA, Leiter LA. Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada. Clinicoecon Outcomes Res. 2023 Apr 20;15:295-308. doi: 10.2147/CEOR.S377935. PMID: 37101608; PMCID: PMC10124620.

Baribeau V, Kim CJ, Lorgeoux RP, Brisebois J, Tossonian H, Lachaine J. Healthcare resource utilization and costs associated with renal, bone and cardiovascular comorbidities among persons living with HIV compared to the general population in Quebec, Canada. PLoS One. 2022 Jul 11;17(7):e0262645. doi:10.1371/journal.pone.0262645. PMID: 35816474; PMCID: PMC9273062.

Lambert-Obry V, Lafrance JP, Savoie M, Lachaine J. The Impact of Hypoglycemia on Productivity Loss and Utility in Patients With Type 2 Diabetes Treated With Insulin in Real-world Canadian Practice: Protocol for a Prospective Study. JMIR Res Protoc. 2022 Mar 28;11(3):e35461. doi: 10.2196/35461. PMID: 35343912; PMCID:PMC9002599.

Simon JA, Ferenczy A, Black D, Castonguay A, Royer C, Marouf R, Beauchemin C. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis. Menopause. 2023 Aug 1;30(8):855-866. doi: 10.1097/GME.0000000000002211. Epub 2023 Jun 27. PMID: 37369079; PMCID: PMC10389189.

Guinan K, Mathurin K, Au Y, Schuh AC, Bui CN, Chai X, Lachaine J. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis. Current Oncology. 2022; 29(10):7524-7536. https://doi.org/10.3390/curroncol29100592

Lachaine J, Beauchemin C, Guinan K, Thebault P, Aw A, Banerji V, Fleury I, Owen C. Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada. Curr Oncol. 2021 Jan 9;28(1):332-345. doi: 10.3390/curroncol28010037. PMID: 33435341

Harasymowycz P, Royer C, Cui AX, Barbeau M, Jobin-Gervais K, Mathurin K, Lachaine J, Beauchemin C. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. Br J Ophthalmol. 2021 Jan 4:bjophthalmol-2020-317262. doi: 10.1136/bjophthalmol-2020-317262. Epub ahead of print. PMID: 33397657.

Beauchemin C, Guinan K, Claveau D, Dufresne SF, Rotstein C. Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada. Expert Rev Pharmacoecon Outcomes Res. 2021 Sep 26:1-10. doi: 10.1080/14737167.2021.1981862. Epub ahead of print. PMID: 34524935.

Beauchemin C, Castonguay A, Chan ES, Dellon ES, Feagan BG, Ma C, Waserman S, Cook J, Claveau D. Economic Evaluation of Budesonide Orodispersible Tablets for the Treatment of Eosinophilic Esophagitis: A Cost-Utility Analysis. Adv Ther. 2021 Dec;38(12):5737-5751. doi: 10.1007/s12325-021-01957-7. Epub 2021 Oct 26. PMID: 34699003

Hillhouse E, Mathurin K, Bibeau J, Parison D, Rahal Y, Lachaine J, Beauchemin C. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review. Adv Ther. 2022 Jan;39(1):455-487. doi: 10.1007/s12325-021-01951-z. Epub 2021 Nov 15. PMID: 34780028; PMCID: PMC8799532.

Poulin Y, Beauchemin C, Royer C, Gaudreau AJ, Yim C, Liu FF, Lachaine J. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization. J Cutan Med Surg. 2020 Nov/Dec;24(6):573-587. doi: 10.1177/1203475420936652. Epub 2020 Jun 29. PMID: 32597685.

Lachaine J, Ben Amor L, Pringsheim T, Burns J, van Stralen J. Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada. J Child Adolesc Psychopharmacol. 2019;29(10):730–739. doi:10.1089/cap.2019.0097

Beauchemin C, Dodat F, Au Y, Evans WK, Paulson K, Schuh AC, Storring J, Lachaine J. Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EE33), May 2022, Washington, United States (In-Person and Virtual Conference)

Guinan K, Mathurin K, Au Y, Schuh AC, Bui CN, Chai X, Lachaine J Venetoclax in Combination with Azacitidine Is Cost-Effective Vs. AZA for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Perspective. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EE46), May 2022, Washington, United States (In-Person and Virtual Conference)

Simon J., Ferenczy A., Black D., Royer C., Castonguay A., Marouf R., Beauchemin C. Endometrial Safety, Efficacy and Tolerability of Ospemifene Compared to Current Therapies for the Treatment of Vulvovaginal Atrophy: A Systematic Literature Review and Network Meta-Analysi. The North American Menopause Society (NAMS) Annual Meeting (pp P78), October 2022, Atlanta, United States

Patenaude J., Gouault Laliberté A., Beauchemin C., Lachaine J., The PROxy Network: A Comunity Pharmacy-Based Network to Facilitate the Generation of Real-World Evidence. Canadian Association for Population Therapeutics (CAPT), November 7-9, 2022, Toronto

Mathurin K, Bloom D, Gross JA, Lachaine J. Economic Impact of Clozapine Treatment Persistence: A Canadian Perspective. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EPH69), May 2023, Boston, United States (In-Person Conference)

Guinan K, Mathurin K, Lachaine J. Economic Impact of Rapid Treatment Initiation of HIV with Bictegravir/Emtricitabine/Tenofovir Aladenamide (B/F/TAF) from a Canadian Healthcare Perspective. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp EPH112), May 2023, Boston, United States (In-Person Conference)

Patenaude J, Gouault Laliberté A, Beauchemin C, Lachaine J. The Impact of Migraine on Canadians' Productivity: A Real-World Pharmacy-Based Study. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PCR72), May 2023, Boston, United States (In-Person Conference)

Guinan K, Mathurin K, Lachaine J. Economic Impact of Rapid Treatment Initiation of HIV with Bictegravir/Emtricitabine/Tenofovir Aladenamide (B/F/TAF) from a Canadian Healthcare Perspective. 32nd Annual Conference on HIV/AIDS Research (CAHR 2023), April 2023, Quebec, Canada - Oral Presentation

Guinan K, Lachaine J, Paul Roc N,  Bull SJ, Tankala D, Barakat S, Hillis CM, Banerji V. The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab. 64th Annual Meeting and Exposition of the American Society of Hematology (ASH 2022), December 2022, New Orleans, United States - Présentation Oral

Patenaude J, Gouault Laliberté A, Beauchemin C, Lachaine J. Real-World Impact of Migraine on Canadians’ Productivity: A Pharmacy-Based Study. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (PCR175), November 2023, Copenhagen, Denmark

Ham M, Pelletier M, Guinan K, Gosselin A, Paul Roc N, Barakat S, Beauchemin C. The Impact of Phase 2 Clinical Trials on Reimbursement Recommendations in Oncology by Canadian Health Technology Assessment Agencies. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (HTA155), November 2023, Copenhagen, Denmark

Patenaude J, Gouault Laliberté A, Beauchemin C, Lachaine J. An Innovative Approach to Generate Patient-Centered Evidence in a Real-World Evidence Setting. Canadian Association for Population Therapeutics (CAPT), October 2023, Toronto, Canada

Harasymowycz P, Saheb H, Matougui K, Beauchemin C, Royer C, Shah-Manek B. Adherence and Persistence to Glaucoma Topical Therapy in Québec, Canada. COS Annual Meeting, June 2023, Québec, Canada.

Saheb H, Harasymowycz P, Matougui K, Beauchemin C, Royer C, Shah-Manek B. Treatment Patterns in Open-Angle Glaucoma Patients Post Initial Diagnosis, Under a Public Insurance Drug Program in Québec, Canada. COS Annual Meeting, June 2023, Québec, Canada.

Desjardins O, Jack C, Netchiporouk E, Veillette H, Baribeau V, Préfontaine D, Labelle M, Lachaine J. Real-World, Longitudinal, Retrospective Study of Healthcare Resource Utilization of Patients With Atopic Dermatitis Under the Public Health Insurance Plan of Quebec, Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (EE257), November 2023, Copenhagen, Denmark

Baribeau V, Mohammed S, Awan A, Parison D, Lachaine J. Drug Utilization, Adherence, and Persistence in Parkinson's Disease Patients in a Real-World Setting in Quebec, Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (P26), November 2023, Copenhagen, Denmark

Baribeau V, Mohammed S, Awan A, Parison D, Lachaine J. Health Care Resource Utilization and Cost in Parkinson's Disease Patients in a Real-World Setting in Quebec, Canada  International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (EE44), November 2023, Copenhagen, Denmark

Lachaine J, Wong G, Baribeau V, Kalia S, Brisebois J, Ringuet J. Retrospective Database Analysis of Healthcare Resource Utilization and Costs in Patients With Vitiligo in Quebec, Canada.International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (EE410), November 2023, Copenhagen, Denmark

Beauchemin C, Guinan K, Mathurin K, Dufresne SF, Rotstein C, Claveau D, Landry L, Lachaine J. Canadian cost-utility analysis of isavuconazole for the treatment of patients with invasive aspergillosis and mucormycosis. Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada). April 2021, Oral Presentation (virtual meeting)

Beauchemin C, Charron JN, Mathurin K, Jobin Gervais K, Barbeau M, Agoumi Y. Cost per Responder Analysis of Latanoprostene Bunod Compared to Prostaglandin Analogs for Open-Angle Glaucoma in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PSS5), Nov. 2020, Milan (virtual meeting)

Beauchemin C, Guinan K, Mathurin K, Dufresne SF, Rotstein C, Claveau D, Landry L, Lachaine. Isavuconazole for the Treatment of Invasive Aspergillosis and Mucormycosis- A Canadian Cost-Utility Analysis. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PIN44), Nov. 2020, Milan (virtual meeting)

Lachaine J, Charron JN, Gregoire JC, Hegele RA, Leiter LA. Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PCV55), Nov. 2020, Milan (virtual meeting)

Beauchemin C, Guinan, Mathurin K, Dufresne SF, Rotstein C, Claveau D, Landry L, Lachaine J. Canadian cost-utility analysis of isavuconazole for the treatment of patients with invasive aspergillosis and mucormycosis. AMMI Canada. April 2021, virtual meeting.

Hillhouse E, Bibeau J, Parison D, Rahal Y, Lachaine J, Beauchemin C. Economic Impact of an Originator-to-Biosimilar Non-Medical Switch in the Real-World Setting- A Systematic Literature Review. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PBI8), Montreal, Canada (virtual meeting)

Mathurin K, Castonguay A, Parison D, Rahal Y, Lachaine J, Beauchemin C. Economic Impact of Originator-to-Biosimilar Non-Medical Switching on Health Care Resource Utilization in Rheumatic Patients in Quebec, Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PBI10), Montreal, Canada (virtual meeting)

Lachaine J, Jain MD, Bibeau J, Marino JP, Ball G Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PCN191), May 2021, Montreal, Canada (virtual meeting)

Schuh AC, Pratz K, Lachaine J, Suh HS, Li X, Chai X, Xie J, Gu C, Bui CN. Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSA49), Copenhagen, Denmark (virtual meeting)

Pratz K, Lachaine J, Suh HS, Li X, Schuh AC, Chai X, Xie J, Yin L, Bui CN. Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSB357), December 2021), Copenhagen, Denmark (virtual meeting)

Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Gu C, Bui CN. Venetoclax Combination Therapies Show Significant Improvements in Overall Survival and Remission in Treatment-Naïve Patients with AML Who Are Ineligible for Intensive Chemotherapy: A Network Meta-Analysis. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSC35), December 2021, Copenhagen, Denmark (virtual meeting)

Patenaude J, Hillhouse E, Aissa F, Filbey S, Lachaine J, Beauchemin C. Economic Evaluation of Biocellulose Wound Dressings for the Management of Chronic Leg Ulcers in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2019, Copenhagen

Lachaine J, Beauchemin C, Guinan K, Thebault P, Aw A, Banerji V, Fleury I, Owen C. Impact of Oral Targeted Therapy on the Economic Burden of CLL in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2019, Copenhagen

Guinan K, Beauchemin C, Tremblay J, Hamet P, Chalmer J, Woodward M, Lachaine J. Economic Evaluation of a New Polygenic Risk Score to Prevent Nephropathies in Type-2 Diabetic Patients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2019, Copenhagen

Stellato D, Thabane M, Beauchemin C, Bornheimer R, Charron JN, Lachaine J, Mathurin K, Delea TE. Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib as Adjuvant Treatment for BRAF V600 Mutation-Positive Melanoma After Surgical Resection in Canada – A Societal Perspective. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Nov 2-6, 2019, Copenhagen

Harasymowycz PJ, Royer C, Jobin Gervais K, Cui A, Barbeau M, Lachaine J, Beauchemin C. Effectiveness of Latanoprostene Bunod in Treating OAG and OHT: Network Meta-Analysis. American Academy od Ophthalmology (AAO), Oct. 12-15, 2019, San Francisco

Royer C, Beauchemin C, Lachaine J, Cui A, Jobin Gervais K, Barbeau M. Latanoprostene Bunod for the Treatment of Open-Angle Glaucoma and Ocular Hypertension – Systematic Literature Review and Network Meta-Analysis. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 18-22, 2019, New Orleans

Beauchemin C, Royer C, Lachaine J, Liu FF, Yim C, Poulin Y. Budget Impact of Use of Apremilast vs. Biologics in the Management of Moderate to Severe Plaque Psoriasis (PsO) in Quebec, Canada, Using Régie de l'assurance maladie du Québec (RAMQ) Administrative Claims Data. 2019 CADTH Symposium, April 14-16, 2019, Edmonton

Mathurin K, Beauchemin C, Lachaine J, Gaudet V, Barbeau M. Cost-effectiveness analysis of eficonazole for the treatment of mild to moderate toenail onychomycosis in Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp PIN33), May 18-22, 2019, New Orleans

Lachance S, Bibeau J, Lachaine J. Burden of Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation on Health Care Resource Utilization in the Management of Acute Leukemia and Myelodysplastic Syndrome. Blood. 128 (22): 2372, 2016.

Lachance, S., Bibeau, J., Ladjemil, N. and Lachaine, J. Impact of cellular therapy on the economic burden and survival following relapse after HLA identical hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndrome. In Haematologica. June 2017. Vol. 102, pp. 126-126.